Physician profile
Ziad Farah
NPI 1700854619
$1,661.20
in general payments reported to CMS, 2019-2025
20 companies · $490 in 2025
The $490 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $41.01 · 2021: $55.00 · 2022: $113 · 2023: $229 · 2024: $582 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $484.40 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $233.01 | 2022-2024 | |
| Novo Nordisk INC | $145.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $128.85 | 2024-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $112.46 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $76.85 | 2024-2025 | Recorlev |
| Lilly USA, LLC | $62.00 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.02 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $55.00 | 2021 | |
| Antares Pharma, INC. | $54.04 | 2024-2025 | Xyosted |
| Soleno Therapeutics, INC. | $48.54 | 2025 | Vykat Xr |
| Abbvie INC. | $45.15 | 2020-2024 | |
| Cequr Corporation | $29.00 | 2024 | Cequr Simplicity |
| Pfizer INC. | $27.02 | 2024 | |
| Medtronic, INC. | $24.74 | 2023 | Minimed 780g |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.11 | 2025 | Dexcom G6 Transmitter |
| Rgh Enterprises LLC | $16.14 | 2025 | |
| Acella Pharmaceuticals, LLC | $14.25 | 2025 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $13.44 | 2019 | |
| Beta Bionics, INC. | $11.15 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.